Lataa...
Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report
BACKGROUND: Dabigatran is a direct thrombin inhibitor with a favorable effectiveness and safety profile when compared to vitamin K antagonists, both in randomized trials and real world registries of atrial fibrillation patients. Yet, physicians’ fear of high bleeding risk scenarios in daily clinical...
Tallennettuna:
| Julkaisussa: | Thromb J |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5583973/ https://ncbi.nlm.nih.gov/pubmed/28878572 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-017-0147-z |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|